Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
603669 Lionco Pharmaceutical Group
- 4.62
- +0.42+10.00%
Market Closed Apr 24 15:00 CST
3.33BMarket Cap-25.52P/E (TTM)
4.62High4.22Low202.74KlotVolume4.26Open4.20Pre Close91.48MTurnover2.81%Turnover RatioLossP/E (Static)721.24MShares9.5452wk High4.70P/B3.33BFloat Cap3.4552wk Low4.62Limit Up721.24MShs Float20.05Historical High3.78Limit Down9.52%Amplitude2.94Historical Low--Dividend TTM4.51Avg Price115.36KlotAsk--Div YieldTTM100Lot Size78.77KlotBid
About Lionco Pharmaceutical Group Company
The company is an innovative enterprise group integrating pharmaceutical R&D, production, sales and medical services. Since its establishment in 2003, it has always adhered to the corporate purpose of “flexible intelligence, focus on health”, and was listed on the Shanghai Stock Exchange in May 2015. The company is mainly engaged in R&D, production and sales of chemical prescription drugs. The company's leading products cover four major fields: parenteral nutritional drugs, anti-infective drugs, digestive medicine, and cardiovascular medicine. The company has successively won honors such as “China's Innovative Pharmaceutical Enterprises” and “China's Top 100 Comprehensive Pharmaceutical Research and Development Strength List”, and Lingkang Pharmaceutical's “An Omeprazole Sodium Hemihydrate and Preparation Method” patent won the China Patent Excellence Award.
Company Profile
Short Name-A灵康药业
Symbol-A603669
Company NameLionco Pharmaceutical Group Co.,Ltd.
Listing DateMay 28, 2015
Issue Price11.70
Shares Offered65.00M share(s)
FoundedDec 24, 2003
Listed ExchangeSH Stock Exchange
Legal Representativelingping tao
General Managerlingping tao
Secretaryguoping sui
Accounting FirmChina Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership)
Securities Representativebaoyu liao
Legal CounselBeijing Zhonglun (Shenzhen) Law Firm
Employees45
Phone0893-7830999;0571-81103508
Office AddressNational Highway No. 349 (Jeba Township section) No. 20, Naidong District, Shannan City, Tibet Autonomous Region
Zip Code856100
Registered AddressNational Highway No. 349 (Jeba Township section) No. 20, Naidong District, Shannan City, Tibet Autonomous Region
Fax0893-7830888;0571-81103508
Emailir@lingkang.com.cn
Websitehttp://www.lingkang.com.cn
Business License540000200018477
BusinessPharmaceutical wholesale; pharmaceutical production; drug contract production; drug retail: drug internet information services; medical research and experimental development; technical services, technology development, technical consultation, technical exchange, technology transfer, technology promotion; housing rental; non-residential real estate leasing; health products (pre-packaged) sales; food sales. (Projects requiring approval according to law can only operate this activity after approval by the relevant departments)
Company Executives
- Name
- Position
- Salary
- lingping tao
- Chairman, Directors, General Manager, Chairman of the Strategy Committee, Member of the Remuneration and Assessment Committee
- 660.00K
- liming liu
- Directors, Deputy General Manager
- 313.90K
- hui zhang
- Directors, Audit Committee Member
- --
- xiaogang tao
- Directors, Deputy General Manager, Strategy Committee Member
- 930.00K
- qian he
- Independent Directors, Audit Committee Member, Chairman of the Remuneration and Assessment Committee
- 120.00K
- chao he
- Independent Directors, Member of the Remuneration and Assessment Committee, Strategy Committee Member, Chairman of the Nomination Committee
- 120.00K
- ziqiang pan
- Independent Directors, Nomination Committee Members, Chairman of the Audit Committee
- 120.00K
- guoping sui
- Board Secretary, Deputy General Manager
- 566.50K
- baoyu liao
- Securities Affairs Representative
- --
- xianjun fang
- Chairman of the Supervisory Board, Auditors
- 207.50K
- yan chen
- Shareholder Supervisors
- 300.10K
- hongsheng wang
- Deputy General Manager
- 400.10K
- junke zhang
- Chief Financial Officer
- 850.00K
- biyu zou
- Employee Supervisors
- 180.00K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs